{
      "Rank": 272,
      "Acronym": [
            "HB-adMSCs"
      ],
      "AgreementOtherDetails": [
            "In the protocol signature page, the investigator agreed to the following: \"I further agree to treat the results of this Study as confidential information and will not submit the results of the Study for publication without prior written authorization from Hope Biosciences. \""
      ],
      "AgreementPISponsorEmployee": [
            "No"
      ],
      "AgreementRestrictionType": [
            "OTHER"
      ],
      "AgreementRestrictiveAgreement": [
            "Yes"
      ],
      "ArmGroupDescription": [
            "Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months."
      ],
      "ArmGroupInterventionName": [
            "Biological: HB-adMSCs"
      ],
      "ArmGroupLabel": [
            "Treatment Arm"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "Female",
            "Male",
            "Hispanic or Latino",
            "Not Hispanic or Latino",
            "Unknown or Not Reported",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported"
      ],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03691909"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [
            "United States",
            "Tender",
            "Swollen"
      ],
      "BaselineDenomCountGroupId": [
            "BG000"
      ],
      "BaselineDenomCountValue": [
            "15"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs) cells."
      ],
      "BaselineGroupId": [
            "BG000"
      ],
      "BaselineGroupTitle": [
            "Treatment Arm"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range"
      ],
      "BaselineMeasureParamType": [
            "Median",
            "Count of Participants",
            "Count of Participants",
            "Count of Participants",
            "Number",
            "Median",
            "Median",
            "Median",
            "Median",
            "Median"
      ],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [
            "Age, Continuous",
            "Sex: Female, Male",
            "Ethnicity (NIH/OMB)",
            "Race (NIH/OMB)",
            "Region of Enrollment",
            "Baseline Tumor Necrosis Factor alpha (TNF-a) in patients with acute RA",
            "Baseline Interleukin-6 (IL-6) in patients with acute RA",
            "Baseline C-Reactive Protein (CRP) in patients with acute RA",
            "Baseline Erythrocyte Sedimentation Rate (ESR) in patients with acute RA",
            "Baseline joint count in patients with acute RA."
      ],
      "BaselineMeasureUnitOfMeasure": [
            "years",
            "Participants",
            "Participants",
            "Participants",
            "participants",
            "pg/mL",
            "pg/mL",
            "mg/L",
            "mm/hr",
            "number of joints"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000",
            "BG000"
      ],
      "BaselineMeasurementLowerLimit": [
            "38",
            "0.88",
            "2.90",
            "4.5",
            "33.0",
            "11.0",
            "8.00"
      ],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [
            "61",
            "3.23",
            "12.1",
            "18.1",
            "55.0",
            "36.0",
            "19.0"
      ],
      "BaselineMeasurementValue": [
            "52",
            "14",
            "1",
            "4",
            "11",
            "0",
            "0",
            "0",
            "0",
            "1",
            "14",
            "0",
            "0",
            "15",
            "1.45",
            "4.90",
            "10.0",
            "43.0",
            "20.0",
            "12.0"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Hope Biosciences is conducting a research study of an investigational product called Hope Biosciences autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment for Rheumatoid Arthritis (RA). The study purpose is to evaluate the safety profile of a single IV infusion of HB-adMSCs in subjects with clinical diagnosis of RA."
      ],
      "BriefTitle": [
            "Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "September 28, 2020"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Rheumatoid Arthritis"
      ],
      "ConditionAncestorId": [
            "D000007592",
            "D000009140",
            "D000012216",
            "D000003240",
            "D000001327",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "All",
            "BC17",
            "BC20"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Arthritis",
            "Rheumatoid Arthritis"
      ],
      "ConditionBrowseLeafId": [
            "M3628",
            "M3632",
            "M9773",
            "M11249",
            "M14197",
            "M5475",
            "M5616",
            "M3781",
            "M9352"
      ],
      "ConditionBrowseLeafName": [
            "Arthritis",
            "Arthritis, Rheumatoid",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Collagen Diseases",
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000001168",
            "D000001172"
      ],
      "ConditionMeshTerm": [
            "Arthritis",
            "Arthritis, Rheumatoid"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [
            "A single IV infusion of autologous adipose-derived mesenchymal stem cells (HB-adMSCs) in subjects with clinical diagnosis of RA."
      ],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "This is a Phase 1/2a, open-label, single-dose study in subjects with active Rheumatoid Arthritis (RA). 12-15 patients will be enrolled for the study. The overall objective of this study is to evaluate the safety profile of a single IV infusion of autologous adipose-derived mesenchymal stem cells (HB-adMSCs) in subjects with clinical diagnosis of RA. The primary endpoint of this study is to measure the number and frequency of adverse event(s) and/or severe adverse event(s) throughout the study duration. The second endpoint of this study is to evaluate the ability of HB-adMSCs to alter RA-related inflammation via measuring levels of Tumor Necrosis Factor alpha (TNF-a), Interleukin-6 (IL-6), C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR) and Joint Count 66/68 after a single infusion of autologous HB-adMSCs for up to 12-month post-infusion."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nAdult male or female between the ages of 18 and 65\n\nPatients have active RA as confirmed by the following criteria:\n\n\u2265 6 swollen joints and \u2265 6 tender joints at screening (68-joint count)\nAbnormal CRP result OR abnormal ESR result at screening. Abnormal CRP result at screening OR abnormal ESR defined as:\nCRP > 4.9 mg/L or ESR > 10mm/hr for men, > 20mm/hr for women\nPatients without current established treatment, or if being treated, patients who are on a stable dose of RA therapy regimen for \u2265 4 weeks prior to screening\n\nExclusion Criteria:\n\nInability to understand and provide signed informed consent\n\nPregnancy, lactation, or, if female of childbearing potential, positive serum \u03b2-hCG at screening.\nCurrently diagnosed any malignant neoplasm. Any patient who was successfully treated for cancer and has been disease-free, with no recurrence, for at least 5 years, will be considered.\n\nUncontrolled systemic illness, including, but not limited to: hypertension (systolic >150 mm Hg or diastolic >95 mm Hg); diabetes; renal, hepatic, or cardiac failure or any laboratory abnormality that poses a safety risk to the subject such as:\n\nHemoglobin \u22648.5 g/dL\nWhite blood cells (WBCs) \u22643,500/mm3 (3.5 G/L)\nAny other illness which, in the opinion of the investigator, characterizes the subject as not being a good candidate for the study\nParticipation in another study with an investigational drug or device within 4 weeks prior to treatment or 5 half-lives of the investigational product used (whichever is longer).\nPositive results of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCV Ab), and/or human immunodeficiency virus antibody (HIV Ab) tests at screening (excluding patients who are tested positive for HBsAb alone due to a hepatitis B vaccination).\nPositive history of Treponema pallidum."
      ],
      "EnrollmentCount": [
            "15"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "0"
      ],
      "EventGroupDeathsNumAtRisk": [
            "15"
      ],
      "EventGroupDescription": [
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs)"
      ],
      "EventGroupId": [
            "EG000"
      ],
      "EventGroupOtherNumAffected": [
            "14"
      ],
      "EventGroupOtherNumAtRisk": [
            "15"
      ],
      "EventGroupSeriousNumAffected": [
            "4"
      ],
      "EventGroupSeriousNumAtRisk": [
            "15"
      ],
      "EventGroupTitle": [
            "Treatment Arm"
      ],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [
            "12 months"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG000",
            "FG000",
            "FG000",
            "FG000",
            "FG000",
            "FG000",
            "FG000",
            "FG000",
            "FG000"
      ],
      "FlowAchievementNumSubjects": [
            "15",
            "15",
            "15",
            "14",
            "13",
            "15",
            "14",
            "13",
            "15",
            "0"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs)."
      ],
      "FlowGroupId": [
            "FG000"
      ],
      "FlowGroupTitle": [
            "Treatment Arm"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "Per Protocol Population Day 1",
            "Per Protocol Population Week 1",
            "Per Protocol Population Week 4",
            "Per Protocol Population Week 8",
            "Per Protocol Population Week 12",
            "Per Protocol Population Week 26",
            "Per Protocol Population Week 52",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [
            "Of 23 screened participants, 15 met inclusion criteria, were enrolled, and given treatment."
      ],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [
            "Participants were recruited based on physician referral and 6 participants were recruited through clinicaltrials.gov. First participant was enrolled on 09/25/2018 and last participant was enrolled on 05/23/2019."
      ],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Treatment Arm"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Hope Biosciences autologous adipose-derived mesenchymal stem cells"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "HB-adMSCs"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "arthritis",
            "stem cells",
            "MSCs",
            "adipose MSCs"
      ],
      "LargeDocDate": [
            "September 24, 2019",
            "November 10, 2021"
      ],
      "LargeDocFilename": [
            "Prot_002.pdf",
            "SAP_003.pdf"
      ],
      "LargeDocHasICF": [
            "No",
            "No"
      ],
      "LargeDocHasProtocol": [
            "Yes",
            "No"
      ],
      "LargeDocHasSAP": [
            "No",
            "Yes"
      ],
      "LargeDocLabel": [
            "Study Protocol",
            "Statistical Analysis Plan"
      ],
      "LargeDocTypeAbbrev": [
            "Prot",
            "SAP"
      ],
      "LargeDocUploadDate": [
            "02/24/2022 10:57",
            "02/24/2022 10:50"
      ],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "March 31, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "March 22, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Hope Biosciences"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Pasadena"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "Accurate Clinical Research"
      ],
      "LocationState": [
            "Texas"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "77034"
      ],
      "MaximumAge": [
            "65 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Hope Biosciences"
      ],
      "OrgStudyId": [
            "HBRA01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "OtherEventNotes": [
            "Rheumatoid Arthritis Flare/Worsening of RA",
            "Staph Infection",
            "Diffuse Rash/Rash on Abdomen",
            "Shortness of Breath",
            "Bowel Blockage",
            "Anemia/Anemia Chronic Disease",
            "Renal Insufficiency",
            "Right Eyelid Pruritis",
            "Cyst Right Ear",
            "Neck Spasm"
      ],
      "OtherEventOrganSystem": [
            "Immune system disorders",
            "Skin and subcutaneous tissue disorders",
            "Skin and subcutaneous tissue disorders",
            "Respiratory, thoracic and mediastinal disorders",
            "Gastrointestinal disorders",
            "Blood and lymphatic system disorders",
            "Vascular disorders",
            "Blood and lymphatic system disorders",
            "Infections and infestations",
            "Renal and urinary disorders",
            "Eye disorders",
            "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "Musculoskeletal and connective tissue disorders",
            "Infections and infestations",
            "Surgical and medical procedures"
      ],
      "OtherEventSourceVocabulary": [
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT"
      ],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000"
      ],
      "OtherEventStatsNumAffected": [
            "2",
            "1",
            "1",
            "1",
            "1",
            "2",
            "2",
            "1",
            "1",
            "2",
            "1",
            "1",
            "1",
            "1",
            "1"
      ],
      "OtherEventStatsNumAtRisk": [
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15",
            "15"
      ],
      "OtherEventStatsNumEvents": [
            "2",
            "1",
            "2",
            "1",
            "1",
            "2",
            "2",
            "1",
            "1",
            "2",
            "1",
            "1",
            "1",
            "1",
            "1"
      ],
      "OtherEventTerm": [
            "Rheumatoid arthritis",
            "Skin Infection",
            "Rash",
            "Dyspnoea",
            "Intestinal Obstruction",
            "Anemia",
            "Hematuria",
            "Thrombocytopenia",
            "Influenza",
            "Renal Failure",
            "Eye Pruritus",
            "Cyst",
            "Muscle Spasms",
            "Tooth Infection",
            "Tooth Extraction"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [
            "Tender Joint Count",
            "Swollen Joint Count"
      ],
      "OutcomeAnalysisGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000"
      ],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [
            "Other",
            "Other",
            "Other",
            "Other",
            "Other",
            "Other"
      ],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [
            "0.743",
            "0.714",
            "0.183",
            "0.775",
            "0.0008",
            "0.003"
      ],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [
            "Effect Size: 0.09",
            "Effect Size: 0.10",
            "Effect Size: 0.37",
            "Effect Size: 0.05",
            "Effect Size: 0.93",
            "Effect Size: 0.83"
      ],
      "OutcomeAnalysisStatisticalMethod": [
            "Wilcoxon-signed rank test",
            "Wilcoxon-signed rank test",
            "Wilcoxon-signed rank test",
            "Wilcoxon-signed rank test",
            "Wilcoxon-signed rank test",
            "Wilcoxon-signed rank test"
      ],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [
            "Total Adverse Events",
            "Mild Adverse Events",
            "Moderate Adverse Events",
            "Severe Adverse Events",
            "Treatment Related Mild Adverse Events",
            "Treatment Related Moderate Adverse Events",
            "Treatment Related Severe Adverse Events",
            "Tender",
            "Swollen"
      ],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000"
      ],
      "OutcomeDenomCountValue": [
            "15",
            "15",
            "15",
            "15",
            "15",
            "15"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs) cells.",
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs)",
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs)",
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs)",
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs)",
            "Single IV administration of Hope Biosciences autologous adipose-derived mesenchymal stem cells (HB-adMSCs)"
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000"
      ],
      "OutcomeGroupTitle": [
            "Treatment Arm",
            "Treatment Arm",
            "Treatment Arm",
            "Treatment Arm",
            "Treatment Arm",
            "Treatment Arm"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "Total number of Adverse Events and Serious Adverse Events across all subjects over 12 months.",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of Tumor Necrosis factor (TNF-a) (pg/mL) measured during trial.",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of interleukin 6 (IL-6) (pg/mL) during the trial",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of C-reactive protein (CRP) (mg/L) during the trial",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of erythrosedimentation rate (ESR) (mm/hr) during the trial.",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of Joint Count 66/68 (# joints - tender and swollen) during the trial."
      ],
      "OutcomeMeasureDispersionType": [
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range",
            "Inter-Quartile Range"
      ],
      "OutcomeMeasureParamType": [
            "Number",
            "Median",
            "Median",
            "Median",
            "Median",
            "Median"
      ],
      "OutcomeMeasurePopulationDescription": [
            "All participants who received treatment and completed at least 5 of 7 follow up assessments.",
            "All participants who received treatment and completed at least 5 of 7 follow up assessments.",
            "All participants who received treatment and completed at least 5 of 7 follow up assessments.",
            "All participants who received treatment and completed at least 5 of 7 follow up assessments.",
            "All participants who received treatment and completed at least 5 of 7 follow up assessments.",
            "All participants who received treatment and completed at least 5 of 7 follow up assessments."
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months"
      ],
      "OutcomeMeasureTitle": [
            "Total Number of Adverse Events and Serious Adverse Events",
            "The Effect of Single Injection of HB-adMSCs on TNF-a in Patients With Acute RA",
            "The Effect of Single Injection of HB-adMSCs on IL-6 in Patients With Acute RA",
            "The Effect of Single Injection of HB-adMSCs on CRP in Patients With Acute RA",
            "The Effect of Single Injection of HB-adMSCs on ESR in Patients With Acute RA",
            "The Effect of Single Injection of HB-adMSCs on Joint Count in Patients With Acute RA."
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "count of events",
            "pg/mL",
            "pg/mL",
            "mg/L",
            "mm/hr",
            "number of joints"
      ],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000"
      ],
      "OutcomeMeasurementLowerLimit": [
            "0.73",
            "2.75",
            "3.00",
            "23.8",
            "0.00",
            "0.00"
      ],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [
            "2.28",
            "13.9",
            "12.0",
            "62.8",
            "4.00",
            "3.00"
      ],
      "OutcomeMeasurementValue": [
            "27",
            "15",
            "8",
            "4",
            "4",
            "0",
            "0",
            "1.15",
            "4.60",
            "6.00",
            "34.5",
            "1.00",
            "1.00"
      ],
      "OverallOfficialAffiliation": [
            "Accurate Clinical Research"
      ],
      "OverallOfficialName": [
            "Philip Waller, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [
            "linette@hopebio.org"
      ],
      "PointOfContactOrganization": [
            "Hope Biosciences Stem Cell Research Foundation"
      ],
      "PointOfContactPhone": [
            "346-900-0340"
      ],
      "PointOfContactPhoneExt": [
            "102"
      ],
      "PointOfContactTitle": [
            "Linette Rehkopf RPh"
      ],
      "PrimaryCompletionDate": [
            "August 17, 2020"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Total number of Adverse Events and Serious Adverse Events across all subjects over 12 months."
      ],
      "PrimaryOutcomeMeasure": [
            "Total Number of Adverse Events and Serious Adverse Events"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months"
      ],
      "ReferenceCitation": [
            "Vij R, Stebbings KA, Kim H, Park H, Chang D. Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial. Stem Cell Res Ther. 2022 Mar 3;13(1):88. doi: 10.1186/s13287-022-02763-w."
      ],
      "ReferencePMID": [
            "35241141"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [
            "March 22, 2022"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [
            "February 24, 2022"
      ],
      "ResultsFirstPostedQCCommentsDateType": [
            "Actual"
      ],
      "ResultsFirstSubmitDate": [
            "August 19, 2021"
      ],
      "ResultsFirstSubmitQCDate": [
            "February 24, 2022"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of Tumor Necrosis factor (TNF-a) (pg/mL) measured during trial.",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of interleukin 6 (IL-6) (pg/mL) during the trial",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of C-reactive protein (CRP) (mg/L) during the trial",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of erythrosedimentation rate (ESR) (mm/hr) during the trial.",
            "Efficacy is a secondary endpoint for this study and will be assessed by comparing the levels of Joint Count 66/68 (# joints - tender and swollen) during the trial."
      ],
      "SecondaryOutcomeMeasure": [
            "The Effect of Single Injection of HB-adMSCs on TNF-a in Patients With Acute RA",
            "The Effect of Single Injection of HB-adMSCs on IL-6 in Patients With Acute RA",
            "The Effect of Single Injection of HB-adMSCs on CRP in Patients With Acute RA",
            "The Effect of Single Injection of HB-adMSCs on ESR in Patients With Acute RA",
            "The Effect of Single Injection of HB-adMSCs on Joint Count in Patients With Acute RA."
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 months",
            "12 months",
            "12 months",
            "12 months",
            "12 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "SeriousEventNotes": [
            "Staph Infection",
            "Bowel Resection",
            "Bowel Blockage",
            "Complicated Urinary Tract Infection"
      ],
      "SeriousEventOrganSystem": [
            "Skin and subcutaneous tissue disorders",
            "Surgical and medical procedures",
            "Gastrointestinal disorders",
            "Gastrointestinal disorders",
            "Renal and urinary disorders"
      ],
      "SeriousEventSourceVocabulary": [
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT",
            "SNOMED CT"
      ],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000"
      ],
      "SeriousEventStatsNumAffected": [
            "1",
            "1",
            "1",
            "1",
            "1"
      ],
      "SeriousEventStatsNumAtRisk": [
            "15",
            "15",
            "15",
            "15",
            "15"
      ],
      "SeriousEventStatsNumEvents": [
            "3",
            "1",
            "1",
            "1",
            "1"
      ],
      "SeriousEventTerm": [
            "Skin Infection",
            "Intestinal Resection",
            "Intestinal Obstruction",
            "Abdominal Pain",
            "Urinary Tract Infection"
      ],
      "StartDate": [
            "September 25, 2018"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "February 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "October 2, 2018"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "September 27, 2018"
      ],
      "StudyFirstSubmitQCDate": [
            "September 28, 2018"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}